Sign in
Active, not recruitingPhase 3

SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial

Key facts

Who runs it
Galaxy Therapeutics INC
Where
Arlington Heights, Camden, Evanston, Naperville, New York, and Stony Brook, United StatesSee the 6 sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
279 people, planned
Started
6 Aug 2024
Expected to end
10 Sept 2030
Type of study
Interventional
Treatments tested
  • The SEAL™ Saccular Endovascular Aneurysm Lattice System
Record updated
16 January 2026

Who can take part

Age
22 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • 22 to 80 years of age at the time of screening
  • Unruptured aneurysm requiring endovascular treatment suitable for SEAL device and meet the American Heart Association (AHA) guidelines for management of unruptured aneurysm.5
  • Ruptured aneurysm A ruptured aneurysm is defined as a patient with computed tomography (CT), magnetic resonance imaging (MRI), or lumbar puncture (LP) evidence of Subarachnoid Hemorrhage (SAH) attributed to the index aneurysm within the last 60 days. Ruptured aneurysm may be included according to the following criteria:; The subject is neurologically stable with no seizure at the onset of the SAH, not requiring External Ventricular Drain (EVD) placement prior to inclusion; Hunt and Hess scale (HHS) of 2 or less at the time of treatment; mRS of ≤2 prior to presentation or aneurysm rupture; Meet the AHA guidelines for management of ruptured aneurysm
  • The index intracranial aneurysm (IA) to be treated must include the following features:; Group A (primary analysis group): The Terminus/ bifurcation location:; 2 mm to 19 mm in equatorial aneurysm width wide neck aneurysm:; Absolute neck size ≥ 4mm and < 9mm AND Dome-to-Neck (DN) ratio ≥1 OR Dome- to-Neck (DN) ratio 1 to 2; Saccular morphology; Located in the anterior or posterior circulation; Group B (Expanded Indication): The Sidewall location:; 2 mm to 19 mm in equatorial aneurysm width wide neck aneurysm:; Absolute neck size ≥ 4mm and < 9mm AND Dome-to-Neck (DN) ratio ≥1 OR Dome- to-Neck (DN) ratio 1 to 2; Saccular morphology; Located in the anterior or posterior circulation
  • Aneurysm treatment does not require the preplanned use of any additional implanted devices
  • Subject is able to maintain compliance with all aspects of screening, evaluation, treatment, and post-procedure follow-up schedule
  • Baseline pre-procedure mRS of 0-2 for unruptured aneurysm and 0-2 prior to the SAH for the ruptured aneurysms
  • Ability to obtain written informed consent document (ICD) subject or legally authorized representative in SAH subjects prior to the initiation of any study procedures

Who cannot take part

  • Aneurysm features unsuitable for endovascular treatment with an intrasaccular device such as fusiform, dissecting pseudo aneurysm, or mycotic aneurysm
  • Patients with untreated multiple aneurysms [≥2mm]. Patient with multiple aneurysms, should have the none index aneurysms treated no less than 60 days prior to enrollment in the SEAL™ IT trial, ≤ 7mm, and not treated with flow diverter or stent assisted endovascular therapy
  • Patients with high risk for recurrent ischemic stroke due to previous history of ischemic stroke symptoms such as TIAs, minor, or major strokes within the past 60 days. Other stroke risk factors such as intracranial stenosis or atrial fibrillation
  • Target index aneurysm that has been previously treated and contains devices, implants, or coils that could interfere with correct SEAL™ device placement
  • Currently on anticoagulation therapy or has a known blood dyscrasia, coagulopathy, or hemoglobinopathy
  • Presence of vascular disease or other vascular abnormality that could prohibit access to index aneurysm such carotid stenosis or diminished caliber of the target artery
  • Clinical, angiographic, or CT evidence of central nervous system (CNS) arterial vasculitis, Moyamoya disease, intracranial tumor (except small meningioma < 3 cm), or any other intracranial vascular malformations
  • Presence of an acute life-threatening illness requiring treatment
  • Subject has an uncontrolled co-morbid medical, neurological, or psychiatric condition, that would adversely affect participation in the study procedures and follow up
  • Subject with a known, uncontrolled hypersensitivity to iodine-based contrast dye, procedure related materials or medications, or device components\^
  • Subjects with history of intracranial bleeding (SAH, SDH or ICH) within 90 days of the index aneurysm treatment; Sensitivity to nickel is not specifically excluded, GTI performed ASTM F2129 testing recommended by the FDA in its 2015 and 2019 guiding documents. GTI results from the testing indicated that SEALTM meets the acceptance criteria that there is a high probability that the margin of safety against pitting (Eb-Er) is 200mV or higher, therefore, with high confidence, no further testing is required. The IFU contains the following precaution: "For patients with known hypersensitivity or allergic reaction to the implant components such as titanium or to nickel, use of the SEALTM System may lead to allergic reaction and user should counsel the patient on the device components"
  • Patients with hemodynamic or medical compromise due to medical comorbidities such as severe unstable congestive heart failure (ejection fraction <30%) or severe chronic obstructive pulmonary disease (COPD) requiring home oxygen
  • Patient with chronic kidney disease (and not on dialysis) with creatinine > 2.0
  • Life expectancy of < 5 years
  • Aneurysms smaller than 2 mm and larger than 19 mm in dome width
  • Inability to access target aneurysm with microcatheter due to intracranial atherosclerosis, proximal or intracranial vessel tortuosity or poor aneurysm angle take-off
  • Patients with two 360 degrees loops in the carotid or vertebral arteries
  • Subject is pregnant or a lactating female (For females of child-bearing potential, a positive pregnancy test within 7 days of the day of procedure or refusal to use a medically accepted method of birth control for the duration of the study
  • Currently enrolled in another investigational study or post-market study that could affect the safety and efficacy of aneurysm treatment or interfere with the study follow-up schedule
  • Subject is a prisoner or member of other vulnerable population
  • The subject that is in the opinion of the treating interventionalist is not suitable for the study

Where in United States

  • Endeavor Health - Northwest Community HospitalArlington Heights, United States
  • The Cooper Health SystemCamden, United States
  • Endeavor Health - Evanston HospitalEvanston, United States
  • Endeavor Health- Edward HospitalNaperville, United States
  • NYU Langone HealthNew York, United States
  • Stony Brook University HospitalStony Brook, United States

About the trial

What the trial wants to find out

To establish the safety and effectiveness of the SEAL™ Saccular Endovascular Aneurysm Lattice system for the treatment of saccular intracranial aneurysms.

Read full original descriptionShow less

The data from this study will be used to support a premarket approval (PMA) submission.

The group in the trial

  • Single arm (The SEAL™ Saccular Endovascular Aneurysm Lattice System)Other group

    Prospective, US and OUS single-arm, multicenter, interventional study.

    Treatment: The SEAL™ Saccular Endovascular Aneurysm Lattice System

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
16 January 2026